MK0767 and Metformin Combination Study (0767-028)

Merck Sharp & Dohme (MSD)

Status and phase

Terminated

Phase 3

Conditions

Diabetes Mellitus

Treatments

Drug: MK0767

Study type

Interventional

Funder types

Industry

Identifiers

NCT00543738

0767-028

2007_639

MK-0767-028

Details and patient eligibility

About

A study to test the effects of MK0767 when added to Metformin in patients with inadequately controlled Type 2 Diabetes Mellitus.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Enrollment

114 patients

Sex

All

Ages

21 to 78 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

All women of childbearing potential must have a negative urine pregnancy test prior to starting the study
Patients must be on a stable dose of metformin for at least 2 weeks prior to visit 2

Exclusion criteria

Patients with a history of type 1 diabetes mellitus and/or history of ketoacidosis
Patients on estrogen replacement therapy regimen or SERM
Patients with history of, allergy to, intolerance or hypersensitivity to statins or fibric acid derivatives, including history of elevated muscle and liver function tests, jaundice, hepatoxicity, or myopathy associated with these treatments
Patient is on a weight loss program with ongoing weight loss or starting an intensive exercise program within 4 weeks from starting the study
Have active liver or gall bladder disease
HIV positive